Ipamorelin vs Egrifta (Tesamorelin) Side-Effect Profile: Head-to-Head Comparison
HealthRX.com
Tesamorelin has labeled side-effect data; ipamorelin has little
At a glance
- FDA status / Tesamorelin: approved in 2010 for excess abdominal fat in HIV-infected adults with lipodystrophy; ipamorelin: not approved [3][6][1]
- Human safety database / Tesamorelin: 740 treated patients in trials, including 543 in the 26-week placebo-controlled phase; ipamorelin: one published surgical trial with 114 analyzed patients and intravenous dosing only [3][4][1]
- Injection-site reactions / Tesamorelin: 25% vs 14% on placebo during the first 26 weeks [1]
- Glucose / Tesamorelin: HbA1c of 6.5% or higher in 5% vs 1% on placebo by week 26 [1]
- IGF-1 / Tesamorelin: 36% had levels above 3 SDS at 26 weeks; the label recommends monitoring IGF-1 [1]
- FDA safety listing / Ipamorelin: category 2 for outsourcing facilities since September 29, 2023 [2][7]
- Sport / Both are named in WADA category S2.2.4 and are prohibited at all times [8][9]
Can the side-effect numbers for the two be compared directly?
Not directly. The ipamorelin numbers come from patients recovering from bowel resection who received intravenous drug [4]. The tesamorelin numbers come from HIV-infected adults with lipodystrophy injecting it under the skin once daily for 26 to 52 weeks [1]. The populations, routes and trial designs all differ.
What the Egrifta labels list as side effects
Both current tesamorelin labels, Egrifta SV and Egrifta WR, are dated July 29, 2026. They state that safety and effectiveness were established from trials of the original 1 mg-per-vial formulation, dosed at 2 mg daily, together with comparable bioavailability for the current formulations [1][10]. The labels say adverse reactions for the current doses are expected to be similar to those seen in those trials [1][10]. The rates below come from the original formulation's trials.
In the combined 26-week placebo-controlled data, the most common reactions and their rates on tesamorelin versus placebo were:
- Joint pain: 13% vs 11%
- Peripheral edema: 6% vs 2%
- Muscle pain: 6% vs 2%
These rates are from the label's combined adverse-reaction table [1].
Injection-site reactions were reported in 25% of tesamorelin-treated patients versus 14% on placebo during the first 26 weeks of the trials [1]. Hypersensitivity reactions occurred in 4%, with itching, redness, flushing, hives and rash; the label says to advise patients to seek prompt medical attention and to stop treatment if one is suspected [1].
The label's warnings section covers the rest of the risk profile:
- IGF-1. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23%. The effects of prolonged IGF-1 elevation are unknown. The label says to monitor IGF-1 and consider stopping for persistent elevation (for example above 3 SDS), particularly if the fat-loss response is not robust [1].
- Glucose. HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6). The label says to evaluate glucose before and during treatment, and to monitor people with diabetes for development or worsening of retinopathy [1].
- Fluid retention. Edema, joint pain and carpal tunnel syndrome can occur [1].
- Neoplasms. Tesamorelin raises growth hormone, a growth factor. Active malignancy is a contraindication, and the label says to stop if cancer recurs [1].
- Critical illness. Increased mortality has been reported when pharmacologic growth hormone was given in acute critical illness, and the label says to consider stopping tesamorelin in critically ill patients [1].
Contraindications are hypothalamic-pituitary axis disruption, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [1]. In trials of the original formulation, anti-tesamorelin antibodies were detected in 50% of patients at 26 weeks, but fat loss and IGF-1 response were similar with or without them [1].
What people on Reddit report
Tesamorelin users describing injection-site burning or stinging, how long it lasted, and whether timing or storage changed it.
For me it's not a small burning sensation. The sting is so much worse than GHK Cu. Stings so bad it feels like bad menstrual cramps. But since I take it before bed it's gone by morning. Nature of the beast I guessRead the source discussion
Yes, normal. It did that for me first week maybe, also a slight burning sensation at first but it went away for me. Didn't feel much first 3 weeks but then on week 4 I woke up like a different person and loved it.Read the source discussion
Questions worth asking
What is actually known about ipamorelin side effects
FDA's review found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin; the human studies used intravenous dosing [3].
The one published trial was a multicenter, double-blind, placebo-controlled phase 2 study in 117 enrolled adults (114 analyzed) after bowel resection. It gave 0.03 mg/kg intravenously twice daily from postoperative day 1 [4]. Per FDA's summary of that trial: low potassium 12.5% on ipamorelin versus 3.4% on placebo, insomnia 10.7% versus 5.2%, high blood sugar at discharge 14.3% versus 8.6%, and serious adverse events 17.9% versus 15.5% [3][4]. Two ipamorelin-treated patients died of surgical complications; FDA said it is unclear whether the deaths were related to the drug but that they raise safety concerns [3].
The trial did not show a significant difference on its main endpoint: median time to first tolerated solid meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo (p=0.15) [4]. Overall treatment-emergent adverse events were reported less often on ipamorelin (87.5%) than on placebo (94.8%) [4].
FDA's compounding concerns add two further risks: possible immunogenicity for certain routes because of peptide aggregation and impurities, and unnatural amino acids that complicate characterization of the molecule [2].
The growth-hormone risks FDA expects from ipamorelin
FDA says ipamorelin stimulates the GH and IGF-1 axis, so it may carry the risks printed on approved growth hormone labels (neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism, pancreatitis and others) and possibly QT prolongation, as with the approved GH stimulator macimorelin. FDA found no data showing it would not [3].
Does ipamorelin spare other pituitary hormones?
Most of the selectivity claims come from animal work. In the 1998 discovery paper, ipamorelin released GH in rats and swine with potency similar to GHRP-6, and in swine it did not change FSH, LH, prolactin or TSH levels [5].
For tesamorelin, the label states that no clinically significant changes in TSH, LH, ACTH or prolactin were observed in patients receiving Egrifta in clinical trials [1]. That statement comes from human trials of a labeled drug.
Route and formulation
Tesamorelin is injected under the skin into the abdomen once daily, rotating sites; the label says rotating sites decreases injection-site reactions [1]. Egrifta SV is 1.4 mg from a 2 mg vial reconstituted with Sterile Water for Injection and given immediately [1]. Egrifta WR is 1.28 mg from an 11.6 mg vial reconstituted with Bacteriostatic Water, and one vial supplies seven daily doses [10]. The labels state the two are not substitutable [10].
Ipamorelin has no approved formulation, no approved dose and no human data for the subcutaneous route [3]. Human studies used intravenous dosing: 0.03 mg/kg twice daily in the ileus trial, and single 15-minute infusions of 4.21 to 140.45 nmol/kg in a volunteer pharmacokinetic study, where GH rose in one sharp peak about 0.67 hours after the infusion [4][11]. Those are study doses, not recommendations.
Regulatory status
FDA added ipamorelin acetate to its category 2 list of bulk substances that may present significant safety risks on September 29, 2023. It is still there on FDA's page dated April 22, 2026 [2] and on the outsourcing-facility list updated March 21, 2025 [7]. On October 29, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, with 1 abstention, on both ipamorelin free base and ipamorelin acetate, citing a lack of information supporting safety and efficacy [12]. Ipamorelin is not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [13].
Tesamorelin is not on FDA's significant-safety-risk list and appears in no category of the compounding lists; it is already the active ingredient of an approved drug [2].
Both are named in WADA's S2.2.4 (growth hormone secretagogues and growth hormone releasing factors) and are prohibited at all times, in and out of competition, on the 2026 and 2027 lists [8][9].
Frequently asked questions
Which one has fewer side effects?
Does ipamorelin leave other pituitary hormones alone?
Does tesamorelin cause diabetes?
Is ipamorelin safer because it is not an approved drug?
What do the labels and FDA say about GH and IGF-1 effects of each?
What is the approved tesamorelin dose?
References
Show all 14 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
- Drugs@FDA: FDA-Approved Drugs.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.
- U.S. Food and Drug Administration.
- Official web page.
- Reddit participants. Tesamorelin Side Effects (r/BodyHackGuide). Accessed 2026-11-10.